HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR MALIGNANT AND NON-MALIGNANT HEMATOLOGIC DISORDERS: A REAL-WORLD EXPERIENCE FROM QATAR (EBMT 2026) - Mar 14, 2026 - Abstract #A260; Pres time: Mar 23, 2026; 06:00 PM - 07:00 PM; Location: VELAZQUEZ; "TBI-based conditioning with fludarabine 160 mg/m² and TBI 1200 cGy were administered to 30 patients (69.8%), whereas 13 patients (30.2%) received non-TBI conditioning...Three patients (7%) had grade 3 CRS and required tocilizumab. Clinically significant CMV infection was significantly higher in patients who did not receive letermovir prophylaxis (92%) than in those who did (11.6%). One patient developed VOD that was treated with defibrotide... Haplo-HCT with PTCy leads to excellent survival for patients who lack HLA-matched donors or access to an unrelated donor. Our results revealed universal engraftment, higher rates of disease-free survival and an improved graft-versus-host disease-free-relapse-free survival. Finally, in our cohort, both chemo and radiotherapy-based conditioning haploidentical cell transplantation resulted in low rates of relapse, non-relapse mortality and chronic GVHD."
Clinical • Post-transplantation • Real-world • Real-world evidence • Acute Graft versus Host Disease • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Transplantation
|
|
Afraa Fadul1; Amaal Gulied1; Awni Alshurafa1; Fatima Taloozy1; Abdul Rashid Shah1; Amna Gamil1; Mohammed Abdulgayoom1; Fabio Culurgioni1; Wedad Saleem1; Manal Yaghmour1; Saloua Hmissi1; Suparna Chandramouli1; Nahrida Band1; Suja Pillai1; Medhat Askar1; Honar Cherif1; Javid Gaziev1; Mohammad Bakr1
|